🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Citi sets price target on Evolent Health stock with buy rating

EditorAhmed Abdulazez Abdulkadir
Published 04/22/2024, 07:04 PM
EVH
-

Monday - Citi has initiated coverage on Evolent Health (NYSE:EVH), a company specializing in value-based care, with a Buy rating and a $40.00 price target. The firm highlights Evolent Health's successful evolution and its establishment of a niche in specialty-focused value-based care, suggesting the company has found its stride after several business model changes.

Evolent Health is seen by the firm as offering a more nuanced approach to specialty utilization management (UM), which could be appealing to health plans looking to control costs without causing friction with patients or providers. The company's methods are described as personalized and evidence-based, contrasting with other more generic and criticized algorithmic approaches.

Citi also appreciates the flexibility of Evolent Health's business model, which includes the ability to take on different levels of clinical risk through its Performance Suite. This adaptability is seen as a key advantage in the healthcare industry.

The firm forecasts substantial growth potential for Evolent Health, driven by its specialty solutions. While administrative solutions are acknowledged as important, the firm expects clinical solutions to remain the primary growth driver for the company.

InvestingPro Insights

Complementing Citi's optimistic outlook on Evolent Health, InvestingPro data underscores significant growth in the company's revenue, with an impressive 45.26% increase over the last twelve months as of Q4 2023. This growth is a testament to the company's evolving business strategies and their effective implementation. With a market capitalization of $3.36 billion, Evolent Health is positioning itself as a notable player in the value-based care sector.

InvestingPro Tips highlight that while Evolent Health has been non-profitable over the last year, analysts are predicting a turn towards profitability this year. This potential shift could be a pivotal moment for the company, aligning with Citi's projection of growth driven by clinical solutions. Additionally, the stock's price volatility is something for investors to keep in mind, as it may offer both opportunities and risks in the market.

For those looking for more in-depth analysis and additional InvestingPro Tips, Evolent Health has a total of 9 tips available on the InvestingPro platform. To access these insights and enhance your investment strategy, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.